Volume 24, Issue 7, Pages (July 2016)

Slides:



Advertisements
Similar presentations
Eleni Galani Medical Oncologist
Advertisements

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
Volume 19, Issue 9, Pages (September 2011)
Molecular Therapy - Oncolytics
Volume 23, Issue 10, Pages (October 2015)
Volume 23, Issue 5, Pages (May 2015)
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Volume 18, Issue 10, Pages (October 2010)
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.
Clinical outcome after SVR: Veterans Affairs
Volume 20, Issue 2, (February 2012)
Volume 19, Issue 4, Pages (April 2011)
Molecular Therapy - Oncolytics
Volume 21, Issue 6, Pages (June 2013)
Volume 119, Issue 4, Pages (October 2000)
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Building better therapy for children with acute lymphoblastic leukemia
Volume 8, Issue 3, Pages (September 2003)
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,
Volume 15, Issue 12, Pages (December 2007)
Volume 119, Issue 4, Pages (October 2000)
Volume 24, Issue 1, Pages (January 2016)
Volume 20, Issue 6, Pages (June 2012)
Volume 17, Issue 2, Pages (February 2009)
Volume 20, Issue 1, Pages (January 2012)
Volume 23, Issue 2, Pages (February 2015)
Volume 24, Issue 8, Pages (August 2016)
Volume 140, Issue 3, Pages e8 (March 2011)
Volume 24, Issue 8, Pages (August 2016)
Tumoral presence of human cytomegalovirus is associated with shorter disease-free survival in elderly patients with colorectal cancer and higher levels.
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Volume 17, Issue 10, Pages (October 2009)
Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?  Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
The Oncofetal Protein IMP3: A Useful Marker to Predict Poor Clinical Outcome in Neuroendocrine Tumors of the Lung  Alessandro Del Gobbo, MD, Valentina.
The predictive value of nadir neutrophil count during treatment of cervical cancer: Interactions with tumor hypoxia and interstitial fluid pressure (IFP) 
Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers  Dong Xie, MD, PhD, Randolph.
Molecular Therapy - Oncolytics
71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice  Mari Hirvinen,
Volume 21, Issue 6, Pages (June 2013)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Volume 20, Issue 6, Pages (June 2012)
Volume 138, Issue 5, Pages e13 (May 2010)
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma  Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.
Volume 18, Issue 2, Pages (February 2010)
Volume 19, Issue 10, Pages (October 2011)
Volume 26, Issue 4, Pages (April 2018)
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Volume 71, Issue 6, Pages (March 2007)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Volume 156, Issue 6, Pages (May 2019)
Volume 22, Issue 1, Pages (January 2014)
Volume 73, Issue 8, Pages (April 2008)
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
Volume 26, Issue 1, Pages (January 2018)
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Volume 15, Issue 1, Pages (January 2007)
Volume 75, Issue 1, Pages (January 2009)
Volume 26, Issue 4, Pages (April 2018)
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus  Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero,
Volume 16, Issue 10, Pages (October 2008)
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma  Leila Khoja, Paul Lorigan, Cong Zhou, Matthew Lancashire, Jessica Booth,
Volume 18, Issue 2, Pages (February 2010)
Volume 24, Issue 8, Pages (August 2016)
Volume 23, Issue 5, Pages (May 2015)
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Volume 24, Issue 7, Pages 1323-1332 (July 2016) Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy  Kristian Taipale, Ilkka Liikanen, Anniina Koski, Raita Heiskanen, Anna Kanerva, Otto Hemminki, Minna Oksanen, Susanna Grönberg- Vähä-Koskela, Kari Hemminki, Timo Joensuu, Akseli Hemminki  Molecular Therapy  Volume 24, Issue 7, Pages 1323-1332 (July 2016) DOI: 10.1038/mt.2016.67 Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Overall survival (OS) and disease control rate in patients with or without baseline neutralizing antiviral antibodies. Patients with zero neutralizing antibody titer in pretreatment samples were considered antibody-negative. (a) Patients with no neutralizing antibodies had longer OS (median OS 239) compared to patients with preexisting neutralizing antibodies (median OS 122, P = 0.022). (b) Overall imaging disease control rate in patients with available neutralizing antibody samples was 50.4% (n = 115). No significant difference between patients with or without preexisting antibodies was observed. (c) Multivariate Cox regression analysis for prognostic value of baseline neutralizing antiviral antibodies. CRC/gastric, colorectal carcinoma and gastric cancer; gynecological, breast cancer, ovarian cancer, endometrial cancer and cervical cancer; HR, hazard ratio; panc/chol/HCC, pancreatic cancer, cholangiocarcinoma and hepatocellular carcinoma. Molecular Therapy 2016 24, 1323-1332DOI: (10.1038/mt.2016.67) Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Overall survival (OS) in different tumor load groups.(a–d) OS was compared between patients with high or low tumor load score and presence or absence of bulky disease, liver metastases, and peritoneal metastases. Patients with low tumor load score had significantly longer OS (P = 0.003), while no significant difference was found between bulky disease (P = 0.260), peritoneal (P = 0.272) or liver metastases (P = 0.065) groups. Molecular Therapy 2016 24, 1323-1332DOI: (10.1038/mt.2016.67) Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Imaging response rates in different tumor load groups. Asterisk indicates P < 0.05. Tumor load and imaging response were evaluable from 148 patients. (a,b) Patients with high or low combined tumor load score or presence or absence of bulky a tumor had no significant differences in disease control rates. (c) Absence of liver metastases before treatment was associated with higher response rate (P = 0.021). (d) Patients with peritoneal metastases had a higher proportion of imaging responses, but the difference was not considered significant (P = 0.094). Molecular Therapy 2016 24, 1323-1332DOI: (10.1038/mt.2016.67) Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Hazard functions obtained from the Cox proportional hazards model. (a) Tumor type had a significant effect on overall hazard for tumor mortality (P = 0.006). Hazard ratios were smaller for gynecological cancers, lung cancer and other cancer types, compared to melanoma, pancreatic/hepatocellular/biliary tract cancers and colorectal/gastric cancers. (b-c) WHO performance status and gender were significant factors in Cox model (P < 0.001 and P = 0.017, respectively). (d) Patients who received virus coding for immunostimulatory transgene as first treatment had smaller hazard ratios compared to other patients (P = 0.001). Molecular Therapy 2016 24, 1323-1332DOI: (10.1038/mt.2016.67) Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Overall survival (OS) in patients with different baseline white blood cell counts. Baseline cell counts were measured 1 day before or on the same day of the first treatment. (a,b) Leucocyte and neutrophil counts that were below median before treatment were associated with significantly longer survival (P = 0.008 and P = 0.002, respectively). (c) No significant difference in OS between different baseline lymphocyte count groups was observed (P = 0.119). (d) Patients with lower than median neutrophil-to-lymphocyte ratio (NLR) had significantly longer OS compared to patients with high NLR (P < 0.001). Molecular Therapy 2016 24, 1323-1332DOI: (10.1038/mt.2016.67) Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions